Can-Fite BioPharma Ltd. filed a Form 6-K on November 18, 2026, reporting that all patients in its pivotal Phase III psoriasis study have completed dosing and that an interim analysis is expected in the first quarter of 2027.
Key Highlights
- All patients completed dosing in Can-Fite's pivotal Phase III psoriasis study, according to the filing.
- Interim analysis expected Q1 2027, as stated in the press release title incorporated by reference in the filing.
- FDA- and EMA-agreed protocol governs the pivotal Phase III psoriasis study, per the filing's description of the press release.
- Press release dated November 18, 2026 was furnished as Exhibit 99.1 and the first three paragraphs were incorporated by reference into the registrant's Form S-8 and Form F-3 registration statements.
- Motti Farbstein, Chief Executive Officer and Chief Financial Officer, signed the filing on behalf of the registrant.
Can-Fite Phase III Psoriasis Study Reaches Full Enrollment Completion
Can-Fite BioPharma Ltd., an Israeli biopharmaceutical company headquartered at 26 Ben Gurion Street, Ramat Gan, Israel, submitted a Form 6-K to the U.S. Securities and Exchange Commission on November 18, 2026. The filing transmits a press release entitled "Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027," furnished as Exhibit 99.1.
According to the filing, the first three paragraphs of the attached press release were incorporated by reference into the registrant's existing registration statements. These include Form S-8 filings under File Nos. 333-227753, 333-271384, and 333-278525, as well as Form F-3 filings under File Nos. 333-236064, 333-276000, 333-281872, 333-262055, 333-294760, 333-298625, and 333-299160. The incorporation is effective from the date the report was submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
The filing was signed by Motti Farbstein, identified as both Chief Executive Officer and Chief Financial Officer of Can-Fite BioPharma Ltd. The company files annual reports under Form 20-F, as indicated on the cover page of the 6-K. No additional financial data or clinical efficacy figures were included in the body of the 6-K itself; the full details of the dosing completion and interim analysis timeline are contained in the press release furnished as Exhibit 99.1.
What Was Disclosed
Can-Fite BioPharma Ltd. disclosed via Form 6-K that all patients in its pivotal Phase III psoriasis trial, conducted under an FDA- and EMA-agreed protocol, have completed dosing, with an interim analysis expected in Q1 2027. A press release was furnished as Exhibit 99.1.




Please wait processing your request...